CIB-L43
CIB-L43 is an orally active TRBP inhibitor (KD = 4.78 nM) and enhances disruption of TRBP-Dicer interactions (IC50 = 2.34 μM) . CIB-L43 suppresses oncogenic miR-21 biosynthesis, increasing PTEN and Smad7 expression and inhibiting AKT and TGF-β signaling, thereby reducing HCC cell proliferation and migration[1].
Product Specifications
CAS Number
[1082942-70-8]
UNSPSC
12352005
Target
Akt; PTEN; TGF-beta/Smad
Related Pathways
PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.71
Solubility
DMSO : 8.93 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
OC(C1=C(N=C(C2=CC=C(C=C2)N3CCOCC3)S1)C)=O
Molecular Formula
C15H16N2O3S
Molecular Weight
304.36
References & Citations
[1]Shi H, et al. Design, Synthesis, and Antitumor Activity Evaluation of 2-Phenylthiazole-5-Carboxylic Acid Derivatives Targeting Transactivation Response RNA-Binding Protein 2. J Med Chem. 2025 Jan 9;68 (1) :421-447.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Rabbit Monoclonal Lambda Light Chain Antibody (IGL/3886R) [PE]](https://cdn.genprice.uk/genprice/genprice2.png)
MBS7008959-01 0.02 mg
Recombinant Streptococcus pneumoniae serotype 19F ATP synthase subunit a (atpB)
Ask
View Details